Scientists at Sanford-Burnham Medical Research Institute have identified a key factor that regulates cells ability to clean themselves of debris and, in turn controls aging. The findings, published in Nature Communications today, could lead to the development of new therapies for age-related disorders that are characterized by a breakdown in this process. This would mean that, while people would still age, their bodies would stay younger longer and their organs remain healthier.
Malene Hansen, Ph.D., associate professor in Sanford-Burnham’s Del E. Webb Center for Neuroscience, Aging and Stem Cell Research, and her team as well as collaborators found a transcription factor—an on/off switch for genes—that induces autophagy in animal models, including the nematode C. elegans, the primary model organism studied in the Hansen lab. This transcription factor, called HLH-30, coordinates the autophagy process by regulating genes with functions in different steps of the process. Two years ago, researchers discovered a similar transcription factor, or orthologue, called TFEB that regulates autophagy in mammalian cells. “These models require active HLH-30 to extend lifespan, possibly by inducing autophagy. We found this activation not only in worm longevity models, but also in dietary-restricted mice, and we propose the mechanism might be conserved in higher organisms as well.”
HLH-30 is the first transcription factor reported to function in all known autophagy-dependent longevity paradigms, strengthening the emerging concept that autophagy can contribute to long lifespan. In a previous study, Hansen and her colleagues discovered that increased autophagy has an anti-aging effect, possibly by promoting the activity of an autophagy-related, fat-digesting enzyme. With these findings, scientists now know a key component of the regulation of autophagy in aging.
Hansen’s team is now working to find therapeutic targets which might actually cause the transcription factor to change its function.
Autophagy has become the subject of intense scientific scrutiny over the past few years, particularly since the process—or its malfunction—has been implicated in many human diseases, including cancer, Alzheimer’s, as well as cardiovascular disease and neurodegenerative disorders. HLH-30 and TFEB may represent attractive targets for the development of new therapeutic agents against such diseases.
The image shows HLH-30 in a laboratory setting.